Concord Biotech Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Concord Biotech Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every ₹100 of sales, ₹61 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹42 tied up three years earlier. More money tied up than 97% of Healthcare companies in India.
- Tangible Net Worth Ratio: Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 86% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹83Over the last 3 years, every ₹100 of reported profit came with ₹83 of operating cash.
Lower than 72% of Healthcare companies in India.
Self-Funding Ratio
2.7×Over the last 3 years its own operating cash covered its investment spending (capex) 2.7 times.
Higher than 76% of Healthcare companies in India.
Cash Locked Ratio
₹61For every ₹100 of sales, ₹61 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹42 tied up three years earlier.
More money tied up than 97% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
₹10Sales grew 26% in 3 years; of every extra ₹100 of sales, ₹10 became extra profit.
Lower than 68% of Healthcare companies in India.
Asset Productivity Ratio
+26% / +48%In 3 years sales changed by +26% while total assets changed by +48%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
No debt dueNo debt falls due within a year, according to the latest yearly balance sheet.
Cash Cushion Ratio
+3%Cash, after subtracting all debt, equals 3% of its market value (net cash).
Higher than 74% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 84% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 86% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Concord Biotech Limited owes ₹0.10 for every ₹1 it owns. Net profit fell 30% in the year to Mar 2026, and grew 3% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
42.3Investors pay ₹42.3 for every ₹1 of Concord Biotech Limited's yearly profit, higher than 60% of Healthcare companies in India.
P/B ratio
6.38The share price is 6.38 times Concord Biotech Limited's book value per share, higher than 71% of Healthcare companies in India.
Market cap
₹12,860 CrThe total market value of all of Concord Biotech Limited's shares at today's price (share price × number of shares), larger than 67% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹2,017 CrWhat Concord Biotech Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹192.81Net worth divided by the number of shares. The share price of ₹1,229 is 6.4 times this, which is the P/B above.
Return on equity (ROE)
15.1%Concord Biotech Limited earned 15.1% on its shareholders' money over the last year, higher than 60% of Healthcare companies in India.
Owes vs Owns
0.10×Concord Biotech Limited owes ₹0.10 for every ₹1 it owns (low), lower than almost all Healthcare companies in India.
Dividend yield
0.55%Concord Biotech Limited pays 0.55% of its share price as dividends a year, higher than 66% of dividend-paying Healthcare companies in India.
Revenue growth
-11%Revenue fell 11% in the year to Mar 2026, and grew 8% a year on average over 3 years.
Profit growth
-30%Net profit fell 30% in the year to Mar 2026, and grew 3% a year on average over 3 years.
Profit margin
24.9%Concord Biotech Limited keeps ₹25 of every ₹100 of revenue as net profit.
Cash quality
1.02×Cash from Concord Biotech Limited's business was 1.02× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
1081.0×Concord Biotech Limited's operating profit covered its interest costs 1081.0 times in the year to Mar 2026.
Cash vs debt
Net cashConcord Biotech Limited held ₹404 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Concord Biotech Limited's P/E ratio?
Investors pay ₹42.3 for every ₹1 of Concord Biotech Limited's yearly profit, higher than 60% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Concord Biotech Limited: ₹12,860 Cr ÷ ₹2,017 Cr (31 Mar 2026) = 6.4.
What is Concord Biotech Limited's return on equity?
Concord Biotech Limited earned 15.1% on its shareholders' money over the last year, higher than 60% of Healthcare companies in India.
How much does Concord Biotech Limited owe compared with what it owns?
Concord Biotech Limited owes ₹0.10 for every ₹1 it owns (low), lower than almost all Healthcare companies in India.
Does Concord Biotech Limited pay a dividend?
Yes. Concord Biotech Limited pays 0.55% of its share price as dividends a year, higher than 66% of dividend-paying Healthcare companies in India.
Is Concord Biotech Limited's revenue growing?
Revenue fell 11% in the year to Mar 2026, and grew 8% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.